Last 26 quarters of trend data · Healthcare · Biotechnology
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
Harmony Biosciences Holdings, Inc.'s quarterly P/E stands at 24.6x, up 143.3% year-over-year — indicating the stock has re-rated higher or earnings have softened. EV/EBITDA has expanded 17.2% YoY to 8.2x, reflecting rising market expectations or slowing EBITDA growth.
| Metric | TTM | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | 10.53 | 24.62 | 7.92 | 11.62 | 10.64 | 10.12 | 12.66 | 37.71 | 12.53 | 17.94 | 13.00 | 15.71 | 17.01 |
| — | +143.3% | -37.4% | -69.2% | -15.1% | -43.6% | -2.7% | +140.1% | -26.3% | +2.9% | +69.1% | -49.7% | -51.1% | |
| P/S Ratio | 1.90 | 2.25 | 1.69 | 2.30 | 2.63 | 2.49 | 3.12 | 2.51 | 3.13 | 2.82 | 3.10 | 3.98 | 4.19 |
| — | -9.5% | -45.9% | -8.3% | -15.9% | -11.8% | +0.7% | -36.9% | -25.4% | -57.3% | -46.4% | -42.6% | -51.4% | |
| P/B Ratio | 1.92 | 2.52 | 1.94 | 2.39 | 2.70 | 3.04 | 3.89 | 3.22 | 3.75 | 4.07 | 4.13 | 4.41 | 4.51 |
| — | -17.0% | -50.2% | -25.9% | -28.2% | -25.3% | -5.7% | -26.8% | -16.8% | -51.7% | -47.6% | -63.4% | -67.2% | |
| P/FCF | 4.74 | — | 3.72 | 5.82 | 14.34 | 6.67 | 8.24 | 10.34 | 15.53 | 6.21 | 7.88 | 14.50 | 11.74 |
| — | — | -54.8% | -43.7% | -7.6% | +7.5% | +4.6% | -28.7% | +32.3% | -80.5% | -35.9% | -34.2% | -54.1% | |
| EV / EBITDA | 3.94 | 8.22 | 3.99 | 6.80 | 6.55 | 7.02 | 7.84 | 14.67 | 7.71 | 9.64 | 6.60 | 9.51 | 10.23 |
| — | +17.2% | -49.1% | -53.6% | -15.0% | -27.2% | +18.8% | +54.3% | -24.6% | -38.1% | -82.1% | -49.1% | -54.0% | |
| EV / EBIT | 4.39 | 8.26 | 4.23 | 6.91 | 6.68 | 7.17 | 7.98 | 15.40 | 7.96 | 8.10 | 7.92 | 10.01 | 10.93 |
| — | +15.2% | -47.0% | -55.1% | -16.1% | -11.4% | +0.7% | +53.9% | -27.1% | -53.8% | -85.7% | -54.6% | -58.7% |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
Harmony Biosciences Holdings, Inc.'s operating margin was 15.8% in Q4 2025, down 11.5 pp QoQ and down 11.9 pp YoY. The trailing four-quarter average of 24.4% exceeds the current quarter, suggesting the latest result may reflect seasonal weakness or a one-off headwind.
| Metric | TTM | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 77.2% | 71.9% | 75.1% | 81.0% | 82.7% | 73.0% | 77.0% | 81.4% | 82.2% | 74.4% | 79.8% | 81.4% | 82.6% |
| — | -1.5% | -2.5% | -0.5% | +0.6% | -1.9% | -3.6% | +0.0% | -0.4% | -5.9% | -0.7% | -1.2% | -0.2% | |
| Operating Margin | 24.0% | 15.8% | 27.3% | 24.0% | 30.4% | 27.7% | 33.2% | 12.4% | 33.7% | 23.9% | 40.3% | 34.9% | 33.9% |
| — | -42.9% | -17.6% | +94.5% | -9.5% | +16.0% | -17.6% | -64.6% | -0.8% | -35.7% | +296.4% | +12.9% | +5.1% | |
| Net Margin | 18.3% | 9.2% | 21.2% | 19.8% | 24.7% | 24.6% | 24.8% | 6.7% | 24.8% | 15.8% | 24.0% | 25.6% | 24.8% |
| — | -62.5% | -14.3% | +195.8% | -0.5% | +55.6% | +3.2% | -73.8% | +0.2% | -58.2% | -68.0% | +16.2% | -1.7% |
| Metric | TTM | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | 20.8% | 2.6% | 6.3% | 5.3% | 6.6% | 7.9% | 8.1% | 2.2% | 7.8% | 5.6% | 8.0% | 7.4% | 7.0% |
| — | -66.5% | -22.1% | +142.2% | -15.4% | +40.4% | +2.0% | -70.2% | +11.9% | -56.8% | -73.3% | -27.6% | -34.9% | |
| ROA | 14.0% | 1.8% | 4.4% | 3.7% | 4.4% | 5.1% | 5.2% | 1.4% | 4.6% | 3.3% | 5.0% | 4.7% | 4.2% |
| — | -64.7% | -14.9% | +170.5% | -4.1% | +53.3% | +3.2% | -70.8% | +8.9% | -54.5% | -67.3% | -4.3% | -11.3% | |
| ROIC | 59.5% | 11.7% | 13.0% | 8.9% | 10.6% | 10.7% | 11.5% | 4.1% | 10.7% | 8.5% | 13.5% | 9.9% | 8.7% |
| — | +9.2% | +12.7% | +119.0% | -1.4% | +25.5% | -14.7% | -59.0% | +23.5% | -25.5% | +259.4% | -23.3% | -30.6% |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
Harmony Biosciences Holdings, Inc.'s Debt/EBITDA ratio is 0.4x, down from 2.4x last quarter — comfortably within a safe range. The current ratio has improved 8.7% YoY to 3.60x, strengthening the short-term liquidity position. Debt/Equity has declined for 9 consecutive quarters, reflecting a deleveraging trend.
| Metric | TTM | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.02 | 0.02 | 0.20 | 0.22 | 0.25 | 0.28 | 0.31 | 0.35 | 0.37 | 0.42 | 0.41 | 0.40 | 0.43 |
| — | -91.6% | -34.5% | -36.1% | -34.2% | -34.5% | -25.2% | -12.1% | -13.4% | -11.7% | -25.6% | -48.7% | -51.7% | |
| Debt / EBITDA | 0.09 | 0.45 | 2.38 | 3.20 | 2.85 | 2.94 | 2.74 | 6.90 | 3.32 | 4.23 | 2.83 | 3.66 | 4.12 |
| — | -84.7% | -13.2% | -53.6% | -14.1% | -30.5% | -3.2% | +88.6% | -19.4% | +18.6% | -73.5% | -25.3% | -29.7% | |
| Current Ratio | 3.60 | 3.60 | 3.75 | 3.84 | 3.67 | 3.31 | 3.24 | 3.13 | 3.11 | 2.75 | 4.12 | 4.90 | 4.90 |
| — | +8.7% | +15.9% | +22.7% | +18.1% | +20.1% | -21.4% | -36.1% | -36.5% | -45.7% | +15.7% | -0.2% | -1.2% | |
| Quick Ratio | 3.58 | 3.58 | 3.72 | 3.80 | 3.63 | 3.27 | 3.20 | 3.09 | 3.07 | 2.72 | 4.07 | 4.84 | 4.85 |
| — | +9.5% | +16.5% | +23.2% | +18.3% | +20.1% | -21.5% | -36.3% | -36.7% | -45.8% | +15.6% | +0.0% | -0.5% | |
| Interest Coverage | 14.23 | 10.87 | 18.09 | 13.21 | 14.66 | 13.24 | 14.19 | 4.85 | 11.47 | 8.38 | 9.20 | 7.54 | 7.05 |
| — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 26 years · Updated daily
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorSee our Bear / Base / Bull DCF models and intrinsic value estimates.
View ValuationCompare performance and metrics against top competitors.
Start ComparisonHarmony Biosciences Holdings, Inc.'s current P/E is 10.5x. The average P/E over the last 4 quarters is 13.7x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
Harmony Biosciences Holdings, Inc.'s current operating margin is 24.0%. Margins have been compressing over recent quarters. Quarterly margins are particularly useful for identifying trend inflections that annual data smooths over.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking Harmony Biosciences Holdings, Inc.'s business trajectory between earnings reports.